WHO ICTRP trial
Further 2 years of adjuvant imatinib may improve recurrence-free survival (RFS)…
EUCTR2014-000898-39-FI · EU Clinical Trials Register · Authorised
Key facts
| Trial ID | EUCTR2014-000898-39-FI |
|---|---|
| Public title | Further 2 years of adjuvant imatinib may improve recurrence-free survival (RFS) of patients who are at a high risk of GIST recurrence despite completion of 3 years of adjuvant imatinib. |
| Scientific title | Three versus five years of adjuvant imatinib as treatment of patients with operable GIST with a high risk for recurrence: A randomised phase III study. |
| Primary sponsor | Scandinavian Sarcoma Group |
| Registry | EU Clinical Trials Register |
| Recruitment status | Authorised |
| Study type | Interventional clinical trial of medicinal product |
| Countries | Finland;Spain;Poland;Belgium;Denmark;Austria;Norway;Netherlands;Germany;United Kingdom;Italy;Sweden |
| Conditions | gastrointestinal stromal tumor (GIST);Therapeutic area: Diseases [C] - Cancer [C04] |
| Interventions | Trade Name: Glivec Product Name: Glivec Product Code: STI571 Pharmaceutical Form: Tablet |
| Registration date | Apr 11, 2014 |
| Target size | 300 |
| Secondary IDs | SSGXXII |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: